# Racial/ethnic differences in pre-pregnancy conditions and adverse maternal outcomes in the nuMoM2b cohort: a population-based cohort study

4 5 Short Title: Pre-Pregnancy Conditions and Adverse Maternal Outcomes 6 7 Meghan E. MEREDITH, BS H. Milton Stewart School of Industrial and Systems Engineering 8 9 Georgia Institute of Technology 755 Ferst Drive, NW Atlanta, GA 30332 10 11 Lauren N. STEIMLE\*, PhD 12 H. Milton Stewart School of Industrial and Systems Engineering 13 Georgia Institute of Technology 14 755 Ferst Drive, NW Atlanta, GA 30332 15 16 Kaitlyn K. STANHOPE, PhD 17 Department of Gynecology & Obstetrics 18 19 Emory University 100 Woodruff Circle, Atlanta, GA 30322 USA 20 21 Marissa H. PLATNER, MD 22 23 Department of Gynecology & Obstetrics 24 Emory University 100 Woodruff Circle, Atlanta, GA 30322 USA 25 26 Sheree L. BOULET, DrPH 27 28 Department of Gynecology & Obstetrics Emory University 29 30 100 Woodruff Circle, Atlanta, GA 30322 USA 31 32 \* Corresponding author: Lauren N. Steimle, steimle@gatech.edu

## 33 Abstract

- 34 **Objective** To: (1) determine how pre-existing conditions contribute to racial disparities
- in adverse maternal outcomes; and (2) incorporate these conditions into models to
- 36 improve risk prediction for racial minority subgroups.
- 37 **Design** Secondary data analysis of a population-based cohort study.
- 38 **Setting** Academic healthcare institutions in the United States.
- 39 **Population** A cohort of 8,729 women included in the "Nulliparous Pregnancy
- 40 Outcomes Study: Monitoring Mothers-to-be (nuMoM2b)".
- 41 *Methods* Poisson regression to estimate adjusted risk ratios, and mediation analysis
- to evaluate the contribution of multimorbidity to racial/ethnic disparities. Area under the
- 43 receiver operating characteristic curve (AUC) to evaluate model performance.
- *Main Outcome Measures* Incidence of severe preeclampsia, postpartum
   readmission, and blood transfusion.

46 **Results** In the nuMoM2b cohort (n=8729), accounting for pre-existing conditions attenuated the association between non-Hispanic Black race/ethnicity and risk of severe 47 48 preeclampsia. Cardiovascular and kidney conditions were associated with risk for severe preeclampsia among all women (aRR, 1.77; CI, 1.61-1.96, and aRR, 1.27; CI, 49 50 1.03-1.56 respectively). The mediation analysis results were not statistically significant; however, cardiovascular conditions explained 36.6% of the association between severe 51 52 preeclampsia and non-Hispanic Black race/ethnicity (p=0.07). The addition of pre-53 pregnancy conditions increased model performance for the prediction of blood transfusion and severe preeclampsia. 54

55 **Conclusions** Pre-existing conditions may explain some of the association between 56 severe preeclampsia and non-Hispanic Black race/ethnicity. Specific pre-pregnancy 57 conditions were associated with adverse maternal outcomes and the incorporation of 58 comorbidities improved the performance of most risk prediction models.

- 59 *Funding* Research reported in this publication was supported in part by Imagine,
- 60 Innovate and Impact (I<sup>3</sup>) from the Emory School of Medicine, Georgia Tech, and through
- 61 the Georgia CTSA NIH award (UL1-TR002378) and by the National Science Foundation
- 62 under grant number DGE-2039655 (Meredith); any opinions, findings, and conclusions
- 63 or recommendations expressed in this material are those of the authors and do not
- 64 necessarily reflect the views of the National Science Foundation.
- 65 *Keywords* Maternal health, Pregnancy Complications, Maternal morbidity, Risk
- 66 Assessment, Multimorbidity, Comorbidity, Chronic Conditions, Health Disparities

## 67 Introduction

The global maternal mortality rate has stalled after improving between 2000 and 2015.<sup>1</sup> 68 69 The United States' maternal mortality rate, 23.8 per 100,000 live births, has worsened over the past 20 years,<sup>2,3</sup> and there are staggering racial and ethnic disparities in 70 71 maternal mortality.<sup>4</sup> In the United States, compared with non-Hispanic white individuals, 72 non-Hispanic Black individuals have 3 to 4 times the risk of dying during childbirth.<sup>5</sup> An estimated 80% of pregnancy-related deaths are considered preventable.<sup>6</sup> and 73 74 individuals with adverse maternal outcomes have similar preventable factors including provider failure to identify high-risk status and inappropriate management.<sup>7</sup> Two 75 76 potential targets for addressing pregnancy-related mortality and morbidity are 77 improvements in chronic condition prevention before and during pregnancy and better 78 prediction models for adverse outcomes that may disproportionally affect racial and 79 ethnic minority individuals. 80 Chronic conditions are associated with a higher risk of adverse maternal outcomes. 81 82 Deliveries among racial and ethnic minorities, compared with non-Hispanic white

83 individuals, experience significantly higher rates of maternal morbidity and also have a higher prevalence of chronic conditions.<sup>8</sup> Pregnant individuals with multiple co-occurring 84 conditions, or *multimorbidity*, have higher rates of severe maternal morbidity and 85 postpartum readmission.<sup>9</sup> While multimorbidity affects a substantial and likely growing 86 proportion of the global adult population,<sup>10</sup> obstetric research and practice remain 87 largely focused on the impact of single conditions on maternal outcomes,<sup>11</sup> apart from a 88 few studies using administrative data, <sup>12,13</sup> and those creating comorbidity-based risk 89 screening tools.<sup>14–16</sup> When multimorbidity is accounted for, it is typically represented as 90 a binary indication of each condition or an indicator of the number of conditions, but 91 92 these representations do not consider the types of co-occurring conditions (e.g. 93 hematological and cardiovascular), which may be more relevant for clinical 94 management.

95

96 In this study, we investigate the impact of pre-pregnancy conditions and their combined

97 effects on adverse maternal outcomes and whether these effects mediate the

98 relationship between racial disparities and adverse maternal outcomes in a cohort of

nulliparous individuals in the United States. A better understanding of which conditions

and combinations thereof drive increased maternal risk could inform the development of

- 101 new clinical care standards for multimorbid pregnant people and potentially improve the
- ability to risk-stratify pregnant people early in pregnancy.
- 103

### 104 Methods

105 Study Population

106 We conducted a secondary analysis of data from the nuMoM2b prospective cohort

107 study of nulliparous women.<sup>17,18</sup> The study recruited women from hospitals affiliated with

- 108 eight clinical centers and collected data on each participant over the course of four
- 109 study visits via in-clinic interviews, self-administered questionnaires, clinical
- 110 measurements, and chart abstractions. The cohort included 9,289 women who
- 111 consented to the release of their data.
- 112

#### 113 Data Preparation

114 For this secondary data analysis, we chose to exclude women who delivered at

115 gestational age < 22 weeks or > 43 weeks and those with terminations and unknown

116 outcomes. We also excluded women with missing race/ethnicity and pre-pregnancy

117 conditions data. To address missing data among confounders, we created 5 imputed

118 datasets using multivariate imputation by chained equations (MICE).<sup>19</sup> Please see

119 Appendix A for more details about the exclusion protocol and Appendix B.1 for more

120 details about the data structure and preparation.

121

#### 122 Main Outcome Measures

123 The primary outcomes of this study were severe preeclampsia, blood transfusion, and 124 postpartum readmission (up to 14 days). These outcomes were selected because they 125 are strongly associated with maternal mortality and morbidity, <sup>20,21</sup> and they have high 126 quality measurements in the nuMoM2b dataset. Appendix B.2 provides details about the 127 definitions and collection of the primary outcomes in the nuMoM2b study.

#### 128

129 We fit prediction models to each of these outcomes individually to preserve the

- 130 interpretability of model results and compared results across each outcome.
- 131

#### 132 Pre-Pregnancy Conditions

Pre-pregnancy conditions were collected by the nuMoM2b study team at each of the first three visits through an in-person interview with the participant, who indicated the presence of each condition at any time throughout their life. The nuMoM2b study team reconciled this data with chart abstraction to finalize the indication of pre-pregnancy conditions.

138

139 The nuMoM2b study team collected 41 pre-pregnancy conditions, and we categorized them into 12 condition types according to the framework of Tang et al.<sup>22</sup> (Appendix 140 141 Table S3). We grouped the pre-pregnancy conditions based on similarities in 142 treatments, clinical manifestation, or organization in the health care system. For example, we grouped cervical dysplasia, fibroids, and PCOS under the condition type 143 144 "Gynecological" because they are conditions that affect the function of female reproductive organs and are treated by the same gynecologist specialty branch. The 145 146 condition types included: Autoimmune, Cardiovascular, Endocrine, Gastrointestinal, 147 Gynecological, Hematologic, Kidney, Lung, Mental, and Neurological. This classification 148 was developed and validated by three of our authors (KS, SB, MP) with extensive medical and specifically obstetric knowledge. 149

150

Our analysis considered pairs of co-occurring pre-pregnancy condition types. For
example, consider a patient with the following three pre-pregnancy conditions: anemia
(hematologic), hypertension (cardiovascular), and migraine headaches (neurological).
This patient was indicated to have the following co-occurring condition types:

hematologic & cardiovascular, cardiovascular & hematologic, and hematologic &

156 neurological.

#### 158 Confounders

159 We adjusted for confounding factors including maternal age, insurance, body mass

- 160 index (BMI), and sociodemographic information including income and education. Each
- 161 of these factors were collected during Visit 1, which occurred between gestational age 6
- and 14 weeks.
- 163
- 164 Statistical Analysis

165 We used Poisson regression models with robust standard errors to analyze the 166 associations between pre-pregnancy condition types, self-reported race/ethnicity, and

167 adverse maternal outcomes with the results reported as crude and adjusted risk ratios

168 (RRs) and 95% confidence intervals (CIs). We used a class-weighting method which

- 169 gives a higher priority to correctly classifying the subgroup of women who experienced
- an adverse maternal outcome (see Appendix B.3).
- 171

172 Potential mediators were selected for each adverse maternal outcome in a stepwise 173 process to avoid multicollinearity. Each adverse maternal outcome was regressed by 174 race/ethnicity, confounders, and all potential mediators (all pre-pregnancy condition types and all their combined effects) (hereafter referred to as the "Outcome Model"). 175 176 Only condition types and combined effects reaching statistical significance (p-value  $\leq$ 177 0.05) in this model were included in further analysis. Additionally, only combined effects 178 with at least 1% prevalence in the dataset were considered. Next, we used a model-179 building approach starting with a standard individual-level Poisson model (Model 1, 180 crude), followed by a Poisson model that adjusted for confounders (Model 2, adjusted). We additionally controlled for significant pre-pregnancy condition types (Model 3), and 181 182 finally, we additionally controlled for significant combined effects between co-occurring 183 pre-pregnancy condition types (Model 4).

184

Next, we sought to determine if pre-pregnancy condition types and their combined
effects contributed to the racial disparities in adverse maternal outcomes using
mediation analysis. To analyze mediation, the potential mediator condition types and
their combined effects were individually regressed by race/ethnicity and adjusted for

189 confounders ("Mediator Model"). The Outcome and Mediator models were combined to

- 190 compute the mediation proportion, which estimates the proportion of the risk factor's
- 191 impact (race/ethnicity) on the outcome that is attributable to the mediator (pre-
- 192 pregnancy condition type or combined effect).<sup>23</sup> This analysis was conducted for each
- adverse maternal outcome and results were averaged across the five imputed datasets.
- 194
- 195 Performance Analysis
- 196 Finally, we analyzed the performance of our prediction models (Model 1, Model 2,
- 197 Model 3, and Model 4) to understand which pre-pregnancy patient characteristics
- accurately classified adverse maternal outcomes. The performance of each model was
- 199 evaluated for each racial/ethnic subgroup using the average area under the ROC curve
- 200 (AUC) across 10-fold cross-validation and across the five imputed datasets.
- 201

We used R, version 4.2.1, for all analysis, *caret* in R to train and test our prediction models and *mediate* in R to conduct mediation analysis. We use a p-value threshold of

- 204 0.05 for statistical significance.
- 205

## 206 **Results**

- After exclusions, the final study population included 8729 women (Table 1). Of those,
- 208 61.0% (n=5322) identified as non-Hispanic white, 13.1% (n=1145) non-Hispanic Black,
- 209 17.0% (n=1487) Hispanic, 3.9% (n = 342) Asian, 4.0% (n=348) multiracial, and 1.0%
- 210 (n=85) "Other". The non-Hispanic Black subgroup had the youngest average age (23.3
- $\pm$  5.3) and the largest average BMI (29.1 ± 8.2). In total, the study population included
- 157 cases (1.8%) of blood transfusion, 154 cases (1.8%) of postpartum readmission,
- and 318 cases (3.6%) of severe preeclampsia. The incidence of these adverse maternal
- outcomes varied by race and ethnicity (Table Appendix S2). The incidence of blood
- transfusion and severe preeclampsia was highest in non-Hispanic Black women and the
- 216 incidence of all adverse maternal outcomes was lowest in Asian women.
- 217

218 The most common pre-pregnancy conditions were mental health conditions (14.4%, 219 n=1261), hematologic conditions (13.8%, n=1206), neurological conditions (13.0%, 220 n=1136), and lung conditions (12.5%, n=1091) (Table Appendix S4). Non-Hispanic 221 Black women experienced the highest rates of lung and hematologic conditions, 222 Hispanic women experienced the highest rates of kidney conditions, and multiracial women experienced the highest rates of cardiovascular conditions. Non-Hispanic white 223 224 women experienced the highest rates of neurological, gastrointestinal, and mental 225 health conditions.

226

227 Of all women, 22.8% (n=1989) had co-occurring pre-pregnancy conditions, i.e., 2 or more conditions. Non-Hispanic white women had the highest rates of co-occurring pre-228 229 pregnancy conditions (24.9%, n=1327), followed by multiracial women (22.7%, n=79), and Non-Hispanic Black women (20.0%, n=229). The most common co-occurring pre-230 pregnancy conditions were Mental & Neurological (3.7%, n=322), Lung & Neurological 231 232 (2.8%, n=248), and Hematologic & Lung (2.5%, n=216) (Table Appendix S5). Among 233 non-Hispanic white women, the most common co-occurring pre-pregnancy conditions 234 were Mental & Neurological (4.7%, n=248), Lung & Neurological (2.9%, n=153), and 235 Hematologic & Lung (2.1%, n=111). Among non-Hispanic Black women, the most common co-occurring pre-pregnancy conditions were Hematologic & Lung (4.4%, n=50) 236 237 and Cardiovascular & Hematologic (3.4%, n=39).

238

239 Compared with non-Hispanic white women, the unadjusted risk of blood transfusion and 240 severe preeclampsia was higher in non-Hispanic Black women. Statistical adjustment 241 for age, sociodemographic information, insurance, and BMI eliminated the elevated risk 242 of blood transfusion in non-Hispanic Black and Hispanic women and eliminated the elevated risk of severe preeclampsia for multiracial women. Statistical adjustment 243 244 attenuated but did not eliminate the elevated risk of severe preeclampsia in non-245 Hispanic Black women. The adjusted relative risk (aRR) of severe preeclampsia was 246 higher in non-Hispanic Black (aRR, 1.22; CI, 1.06-1.41) compared to non-Hispanic 247 white women (Table 4).

After adjusting for confounders, we controlled for pre-pregnancy condition types (Model

- 3) and their combined effects (Model 4). Controlling for pre-pregnancy condition types
- 251 for the outcome of severe preeclampsia attenuated the risk of severe preeclampsia in
- non-Hispanic Black women (aRR 1.15, CI, 0.99-1.34) (Table 6).
- 253

254 Pre-pregnancy condition types were associated with adverse maternal outcomes (see

Tables 2-4). Autoimmune conditions significantly increased the risk for blood transfusion

256 (aRR, 1.36; CI, 1.04-1.78) and postpartum readmission (aRR, 1.55; CI, 1.22-1.97).

257 Hematologic conditions were associated with a significantly increased risk for blood

transfusion (aRR, 1.42; CI, 1.23-1.64). Cardiovascular and kidney conditions were

associated with a significantly increased risk for severe preeclampsia (aRR, 1.77; CI,

260 1.61-1.96, and aRR, 1.27; CI, 1.03-1.56 respectively). Accounting for combined effects

261 did not significantly impact effect estimates.

262

Mediation analysis was conducted on all statistically significant condition types and combined effects for each adverse maternal outcome. There were no significant results at p-value < 0.05; however, cardiovascular conditions accounted for 36.6% of the association between non-Hispanic Black race/ethnicity and severe preeclampsia at pvalue 0.07.

268

269 Finally, we compared the performance metrics, specifically the area under the receiver 270 operating characteristics curve (AUC), of models with different feature sets to determine 271 the value of different maternal characteristics in predicting the risk of experiencing each 272 of the adverse maternal outcomes (Table Appendix S6). We found gains in overall AUC 273 with the addition of condition types for the prediction of blood transfusion and severe 274 preeclampsia (AUC, 0.55 to 0.59, 0.61 to 0.65, respectively). We computed AUC for 275 each racial and ethnic subgroup to understand how the models performed across the 276 subgroups. AUC varies significantly by race for each adverse maternal outcome. Model 277 3, which includes race, confounders, and condition types as features, has an AUC range of 0.50-0.67 for blood transfusion, 0.45-0.63 for postpartum readmission, and 278

- 279 0.49-0.70 for severe preeclampsia. The largest improvement in AUC from adding
- condition was in predicting blood transfusion in Multiracial women, from 0.49 to 0.67.

## 281 **Discussion**

282 Main Findings

Our findings suggest accounting for pre-pregnancy condition types explained some of
the association between non-Hispanic Black race/ethnicity and severe preeclampsia.
We found that including pre-pregnancy condition types improved diagnostic ability
(AUC) in predictive models for blood transfusion and severe preeclampsia, both for the

overall cohort and for most individual racial and ethnic groups. These results highlight

- the potential for risk prediction using pre-pregnancy conditions in a diverse, but low-riskpopulation.
- 290

Consistent with previous studies,<sup>5,8,24–26</sup> we found that identification as a minority race 291 292 was associated with a higher risk of adverse maternal outcomes among a cohort of 293 nulliparous individuals. Adding to some studies that have examined the impact of specific co-occurring condition combined effects,<sup>27,28</sup> our study focused on exploring all 294 295 potential pre-pregnancy condition type combined effects to understand their association 296 with adverse maternal outcomes (specifically severe preeclampsia, postpartum 297 readmission, and blood transfusion) and quantified the value of including combined 298 effects in predictive models. No pre-pregnancy condition combined effects were 299 significantly associated with adverse maternal outcomes.

300

We also quantified the association between individual pre-pregnancy condition type and adverse maternal outcomes. Each adverse maternal outcome was associated with different pre-pregnancy condition types, except the autoimmune condition type, which was associated with increased risk for both blood transfusion and postpartum readmission. It is well known that pregnancy is associated with changes in the maternal immune system, and specifically the postpartum period is associated with autoimmune disease flares.<sup>29</sup>

309 Our work adds to previous studies on the use of prediction models to predict various adverse outcomes, which have ranged from using symptoms and signs,<sup>14,16</sup> laboratory 310 tests and biomarkers,<sup>30,31</sup> and demographics and medical history.<sup>32,33</sup> With the inclusion 311 of pre-pregnancy condition types, our model yields an AUC of 0.65 for predicting severe 312 313 preeclampsia, which is comparable to the AUC of previously published obstetric comorbidity indices predicting SMM, which included severe preeclampsia (Bateman, et 314 al.<sup>15</sup>: AUC, 0.65 and Easter, et al.<sup>14</sup>: AUC, 0.70 as reported by Leonard et al.<sup>34</sup>). The 315 prediction models for blood transfusion and severe preeclampsia improved with the 316 317 addition of pre-pregnancy condition types; however, the model for postpartum 318 readmission did not improve.

319

320 Interpretation

Understanding the potential reasons for adverse maternal outcomes is an important
 pathway to understanding and reducing racial and ethnic disparities and high rates of
 maternal morbidity and mortality.

324

325 Our findings suggest that the presence of pre-pregnancy conditions and confounders may explain some of the observed association between non-Hispanic Black 326 327 race/ethnicity and severe preeclampsia. In a prior study, Black race was associated with increased odds of pregnancy-induced hypertension after adjustment for preexisting 328 conditions and demographic factors.<sup>35</sup> However, our study adjusts for a different set of 329 preexisting conditions. The prevention and management of these pre-existing 330 331 conditions, specifically cardiovascular conditions, before, during, and between pregnancies could be an important consideration to decrease racial and ethnic 332 333 disparities in adverse maternal outcomes. Although the nuMoM2b cohort study 334 collected data on a wide range of pre-pregnancy conditions, we could not explain a 335 large proportion of the disparities in maternal morbidity in this cohort. Future work may 336 benefit from the inclusion of additional data such as the severity and management of 337 morbidity and multimorbidity during the preconception, interconception, and postpartum 338 periods to determine whether differential management reduces the observed disparities.

340 Our work suggests that information about pre-pregnancy conditions can be useful in

improving the ability to risk-stratify individuals. The use of predictive modeling may be

342 useful to further explore the complex relationships of co-occurring conditions. However,

343 more research is necessary to inform best clinical practice for the use of predictive

models with a focus on mitigating unintended consequences and preventing the

345 exacerbation of disparities.<sup>36</sup>

346

#### 347 Strengths and Limitations

Our study has several strengths. Using a large and comprehensive dataset, we
evaluated the association between race and ethnicity, pre-pregnancy conditions, and
adverse maternal outcomes in a cohort of nulliparous women in the United States. This

351 dataset contains thoroughly collected data that goes beyond a typical electronic health

record including health history and conditions, demographics, and survey

353 questionnaires. Our condition type groupings allowed for larger sample sizes of

354 conditions and more accurate estimates of risk ratios. In addition, the use of feature

355 selection algorithms allowed for the exploration of combined effects to improve model

356 performance for predicting adverse maternal outcomes.

357

358 Our study has several important limitations. First, the analysis was limited to the data 359 collected in the nuMoM2b dataset, which only includes nulliparous, predominantly non-360 Hispanic white women who received regular prenatal care at academic medical centers 361 and began care before 13 weeks and 6 days gestation; thus, our findings may not be 362 generalizable to different birthing populations. Second, the nuMoM2b dataset also does not indicate the severity or long-term treatment status of pre-pregnancy conditions. 363 364 Third, our dataset only collected data up to 14 days postpartum, although many postpartum readmissions occur after this timespan.<sup>37</sup> Finally, adverse pregnancy 365 outcomes are rare and occur infrequently in the nuMoM2b dataset, particularly as we 366 367 stratified by racial subgroups and by multimorbidity. A larger sample size may be able to 368 identify more statistically significant associations between pre-pregnancy conditions and 369 maternal outcomes that occur infrequently.

## 370 **Conclusion**

- 371 In addition to describing associations between race and ethnicity, pre-pregnancy
- 372 condition types and their combined effects, and adverse maternal outcomes, our
- 373 findings indicate that pre-pregnancy conditions may partially explain the association
- 374 between severe preeclampsia and non-Hispanic Black race/ethnicity. Additionally, data
- 375 collected at an initial prenatal care visit has utility for predicting the risk of experiencing
- an adverse maternal outcome. Our study findings have important implications for the
- 377 preconception care as well as antepartum care of individuals with pre-existing
- 378 conditions as adequately assessing a patient's risk is essential to providing risk-
- appropriate and equitable care to prevent adverse maternal outcomes.
- 380

## 381 Acknowledgments

- 382 None.
- 383

## 384 **Disclosure of Interests**

- 385 The authors report no disclosures of interest.
- 386

# 387 **Contribution to Authorship**

All authors were involved in the literature search and in the design of the study. MM and LNS obtained the data and MM performed the data analysis. MM drafted the manuscript with LNS. KS, MP, and SH revised the manuscript for important intellectual content, and all authors were involved in the interpretation of the results. All authors approved the final version to be published.

393

# **Details of Ethics Approval**

395 This study was approved by the Georgia Institute of Technology Internal Review Board

- 396 which deemed it exempt from review.
- 397

## 398 Funding

- 399 Research reported in this publication was supported in part by Imagine, Innovate and
- 400 Impact (I<sup>3</sup>) from the Emory School of Medicine, Georgia Tech, and through the Georgia
- 401 CTSA NIH award (UL1-TR002378) and by the National Science Foundation under grant
- 402 number DGE-2039655 (Meredith); any opinions, findings, and conclusions or
- 403 recommendations expressed in this material are those of the authors and do not
- 404 necessarily reflect the views of the National Science Foundation.

## 405 **References**

- Trends in Maternal Mortality 2000 to 2020, Estimates by WHO, UNICEF, UNFPA, World
   Bank Group and UNDESA/Population Division.; 2023.
- Pregnancy Mortality Surveillance System | Maternal and Infant Health | CDC. Accessed
   May 18, 2022. https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy mortality-surveillance-system.htm
- 411 3. Hoyert L. D. *Maternal Mortality Rates in the United States, 2019.*; 2021.
- 412 doi:10.15620/CDC:103855
- 4. Petersen EE, Davis NL, Goodman D, et al. Racial/Ethnic Disparities in Pregnancy-Related
  414 Deaths United States, 2007–2016. *MMWR Morb Mortal Wkly Rep*. 2019;68(35):762415 765. doi:10.15585/MMWR.MM6835A3
- Liese KL, Mogos M, Abboud S, Decocker K, Koch AR, Geller SE. Racial and Ethnic
  Disparities in Severe Maternal Morbidity in the United States. *J Racial Ethn Health Disparities*. 2019;6(4):790-798. doi:10.1007/S40615-019-00577-W
- 419 6. Trost S, Beauregard J, Chandra G, et al. *Pregnancy-Related Deaths: Data from Maternal*420 *Mortality Review Committees in 36 US States, 2017-2019.*; 2017.
- Geller SE, Rosenberg D, Cox S, Brown M, Simonson L, Kilpatrick S. A scoring system
   identified near-miss maternal morbidity during pregnancy. *J Clin Epidemiol*.
   2004;57(7):716-720. doi:10.1016/J.JCLINEPI.2004.01.003
- Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK. Racial and ethnic
   disparities in the incidence of severe maternal morbidity in the United States, 2012-2015.
   *Obstetrics and Gynecology*. 2018;132(5):1158-1166.
- 427 doi:10.1097/AOG.00000000002937
- Stanhope KK, Worrell N, Jamieson DJ, Geary FH, Boulet SL. Double, Triple, and Quadruple
  Jeopardy: Entering Pregnancy With Two or More Multimorbid Diagnoses and Increased
  Risk of Severe Maternal Morbidity and Postpartum Readmission. *Women's Health Issues*.
  Published online July 11, 2022. doi:10.1016/J.WHI.2022.06.005
- 432 10. *Multimorbidity: A Priority for Global Health Research*.; 2018.
- 433 11. Brown HK, McKnight A, Aker A. Association between pre-pregnancy multimorbidity and
  434 adverse maternal outcomes: A systematic review. *Journal of multimorbidity and*435 *comorbidity*. 2022;12:26335565221096584. doi:10.1177/26335565221096584
- 436 12. Admon L, Winkelman T, Moniz M, Davis M, Heisler M, Dalton V. Chronic Disease
  437 Prevalence Among Mothers Delivering in the United States, 2004-2013 [38N]. Obstetrics
  438 & *Gynecology*. 2017;129(1):S152-S153. doi:10.1097/01.AOG.0000514748.00812.AE
- 439 13. Brown CC, Adams CE, George KE, Moore JE. Associations Between Comorbidities and
  440 Severe Maternal Morbidity. *Obstetrics and gynecology*. 2020;136(5):892-901.
  441 doi:10.1097/AOG.00000000004057
- 442 14. Easter SR, Bateman BT, Sweeney VH, et al. A comorbidity-based screening tool to predict
  443 severe maternal morbidity at the time of delivery. *Am J Obstet Gynecol*.
  444 2019;221(3):271.e1-271.e10. doi:10.1016/J.AJOG.2019.06.025
- 444 2019,221(3).271.81271.810. doi:10.1010/3.AJOG.2019.00.023 445 15. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a Comorbidity Index for
- 446 Use in Obstetric Patients. *Obstetrics and gynecology*. 2013;122(5):957-965.
- 447 doi:10.1097/AOG.0B013E3182A603BB

448	16.	Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric
449		Comorbidity Scoring System for Predicting Severe Maternal Morbidity. Obstetrics and
450		gynecology. 2020;136(3):440. doi:10.1097/AOG.0000000000004022
451	17.	Goretsky A, Dmitrienko A, Tang I, et al. Data Preparation of the nuMoM2b Dataset.
452		medRxiv. Published online August 26, 2021:2021.08.24.21262142.
453		doi:10.1101/2021.08.24.21262142
454	18.	Haas DM, Parker CB, Wing DA, et al. A description of the methods of the Nulliparous
455		Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). Am J Obstet
456		<i>Gynecol</i> . 2015;212(4):539.e1-539.e24. doi:10.1016/J.AJOG.2015.01.019
457	19.	van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure
458		covariates in survival analysis. STATISTICS IN MEDICINE Statist Med. 1998;18:681-694.
459		doi:10.1002/(SICI)1097-0258(19990330)18:6
460	20.	Matas JL, Mitchell LE, Sharma S V., Louis JM, Salemi JL. Severe maternal morbidity at
461		delivery and postpartum readmission in the United States. <i>Paediatr Perinat Epidemiol</i> .
462		2021;35(6):627-634. doi:10.1111/PPE.12762
463	21.	Dzakpasu S, Deb-Rinker P, Arbour L, et al. Severe maternal morbidity surveillance:
464		Monitoring pregnant women at high risk for prolonged hospitalisation and death.
465		Paediatr Perinat Epidemiol. 2020;34(4):427. doi:10.1111/PPE.12574
466	22.	Tang LH, Thygesen LC, Willadsen TG, et al. The association between clusters of chronic
467		conditions and psychological well-being in younger and older people-A cross-sectional,
468		population-based study from the Lolland-Falster Health Study, Denmark. J Comorb.
469		2020;10:2235042X20981185. doi:10.1177/2235042X20981185
470	23.	Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal
471		Mediation Analysis. J Stat Softw. 2014;59(5):1-38. doi:10.18637/JSS.V059.I05
472	24.	Creanga AA, Bateman BT, Kuklina E v., Callaghan WM. Racial and ethnic disparities in
473		severe maternal morbidity: a multistate analysis, 2008-2010. Am J Obstet Gynecol.
474		2014;210(5):435.e1-435.e8. doi:10.1016/J.AJOG.2013.11.039
475	25.	Leonard SA, Main EK, Scott KA, Profit J, Carmichael SL. Racial and ethnic disparities in
476		severe maternal morbidity prevalence and trends. Ann Epidemiol. 2019;33:30-36.
477		doi:10.1016/J.ANNEPIDEM.2019.02.007
478	26.	Grobman WA, Bailit JL, Rice MM, et al. Racial and Ethnic Disparities in Maternal
479		Morbidity and Obstetric Care. Obstetrics and gynecology. 2015;125(6):1460.
480		doi:10.1097/AOG.00000000000735
481	27.	Prophet J, Kelly K, Domingo J, et al. Severe pre-eclampsia among pregnant women with
482		sickle cell disease and HIV. Pregnancy Hypertens. 2018;11:87-91.
483		doi:10.1016/J.PREGHY.2018.01.006
484	28.	Czerwinski S, Gollero J, Qiu C, Sorensen TK, Williams MA. Migraine-Asthma Comorbidity
485		and Risk of Hypertensive Disorders of Pregnancy. J Pregnancy. 2012;2012.
486		doi:10.1155/2012/858097
487	29.	Borba VV, Zandman-Goddard G, Shoenfeld Y. Exacerbations of autoimmune diseases
488		during pregnancy and postpartum. Best Pract Res Clin Endocrinol Metab. 2019;33(6).
489		doi:10.1016/j.beem.2019.101321

490 491 492	30.	Schmidt LJ, Rieger O, Neznansky M, et al. A machine-learning–based algorithm improves prediction of preeclampsia-associated adverse outcomes. <i>Am J Obstet Gynecol</i> . 2022;227(1):77.e1-77.e30. doi:10.1016/j.ajog.2022.01.026
492	31.	Binder J, Kalafat E, Palmrich P, Pateisky P, Khalil A. Angiogenic markers and their
494	51.	longitudinal change for predicting adverse outcomes in pregnant women with chronic
494		hypertension. Am J Obstet Gynecol. 2021;225(3):305.e1-305.e14.
495		doi:10.1016/j.ajog.2021.03.041
490 497	32.	Sheen JJ, Wright JD, Goffman D, et al. Maternal age and risk for adverse outcomes. Am J
498	52.	Obstet Gynecol. 2018;219(4):390.e1-390.e15. doi:10.1016/j.ajog.2018.08.034
498	33.	Erickson EN, Carlson NS. Maternal Morbidity Predicted by an Intersectional Social
500	55.	Determinants of Health Phenotype: A Secondary Analysis of the NuMoM2b Dataset.
501		Reprod Sci. Published online 2022. doi:10.1007/S43032-022-00913-2
501	34.	Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric
502	54.	Comorbidity Scoring System for Predicting Severe Maternal Morbidity. <i>Obstetrics and</i>
503		gynecology. 2020;136(3):440-449. doi:10.1097/AOG.000000000004022
504	35.	Minhas AS, Ogunwole SM, Vaught AJ, et al. Racial Disparities in Cardiovascular
505	55.	Complications with Pregnancy-Induced Hypertension in the United States. <i>Hypertension</i> .
507		2021;78(2):480-488. doi:10.1161/HYPERTENSIONAHA.121.17104
508	36.	Jean-Francois B, Bailey Lash T, Dagher RK, Green Parker MC, Han SB, Lewis Johnson T.
508	50.	The Potential for Health Information Technology Tools to Reduce Racial Disparities in
510		Maternal Morbidity and Mortality. J Womens Health. 2021;30(2):274.
510		doi:10.1089/JWH.2020.8889
512	37.	Declercq ER, Cabral HJ, Cui X, et al. Using Longitudinally Linked Data to Measure Severe
513	57.	Maternal Morbidity. <i>Obstetrics and gynecology</i> . 2022;139(2):165-171.
514		doi:10.1097/AOG.000000000004641
714		

# 516 **Tables**

517 Table 1: Descriptive Statistics of the nuMoM2b Study Population by race/ethnicity status (before imputing missing data).

518 BMI, body mass index; Std, standard deviation; HS, high school

				Non-Hispanic	Non-Hispanic	
	Asian	Hispanic	Multiracial	Black	White	Other
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Total	342 (3.9%)	1487 (17.0%)	348 (4.0%)	1145 (13.1%)	5322 (61.0%)	85 (1.0%)
Education						
Degree work beyond college	158 (46.2%)	148 (10.0%)	56 (16.1%)	73 (6.4%)	1546 (29.1%)	23 (27.1%)
Completed college	110 (32.2%)	249 (16.8%)	68 (19.5%)	117 (10.2%)	1835 (34.5%)	26 (30.6%)
Some college	31 (9.1%)	443 (29.8%)	87 (25.0%)	336 (29.3%)	795 (14.9%)	12 (14.1%)
Assoc/Tech degree	29 (8.5%)	165 (11.1%)	29 (8.3%)	114 (10.0%)	543 (10.2%)	7 (8.2%)
HS grad or GED	9 (2.6%)	271 (18.2%)	47 (13.5%)	291 (25.4%)	391 (7.4%)	10 (11.8%)
Less than HS grad	4 (1.2%)	206 (13.9%)	61 (17.5%)	214 (18.7%)	212 (4.0%)	6 (7.1%)
Missing	1 (0.3%)	5 (0.3%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Gravidity						
1	262 (76.6%)	1014 (68.2%)	250 (71.8%)	798 (69.7%)	4116 (77.3%)	63 (74.1%)
2	61 (17.8%)	334 (22.5%)	77 (22.1%)	226 (19.7%)	937 (17.6%)	16 (18.8%)
3 +	19 (5.6%)	139 (9.4%)	21 (6.0%)	121 (10.6%)	269 (5.1%)	6 (7.1%)
Insurance						
Government	34 (9.9%)	825 (55.5%)	147 (42.2%)	692 (60.4%)	764 (14.4%)	25 (29.4%)
Commercial	289 (84.5%)	593 (39.9%)	178 (51.2%)	383 (33.5%)	4406 (82.8%)	54 (63.5%)
Self-pay	86 (25.2%)	144 (9.7%)	47 (13.5%)	71 (6.2%)	1130 (21.2%)	15 (17.7%)
Other	8 (2.3%)	31 (2.1%)	11 (3.2%)	34 (3.0%)	87 (1.6%)	2 (2.4%)
Type of Labor						
Spontaneous, not	69 (20.2%)	270 (18.2%)	67 (19.3%)	168 (14.7%)	953 (17.9%)	15 (17.7%)
augmented						
Spontaneous, augmented	164 (48.0%)	650 (43.7%)	130 (37.4%)	462 (40.4%)	2181 (41.0%)	32 (37.7%)
Induced	81 (23.7%)	475 (31.9%)	131 (37.6%)	463 (40.4%)	1808 (34.0%)	33 (38.8%)
Cesarean w/o labor or induction	28 (8.2%)	91 (6.1%)	20 (5.8%)	51 (4.5%)	379 (7.1%)	5 (5.9%)
Mode of Delivery						
Vaginal	234 (68.4%)	1046 (70.3%)	264 (75.9%)	788 (68.8%)	3923 (73.7%)	55 (64.7%)
Cesarean	. ,	. ,	. ,	. ,	. ,	. ,
Planned or scheduled	19 (5.6%)	60 (4.0%)	11 (3.2%)	32 (2.8%)	282 (5.3%)	3 (3.5%)
Unscheduled, non-urgent	49 (14.3%)	188 (12.6%)	44 (12.6%)	181 (15.8%)	702 (13.2%)	21 (24.7%)
Unscheduled, urgent	40 (11.7%)	193 (13.0%)	29 (8.3%)	144 (12.6%)	411 (7.7%)	6 (7.1%)
-	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std
Age	31.0 ± 4.7	24.8 ± 5.52	25.0 ± 6.2	23.3 ± 5.3	28.2 ± 5.2	27.9 ± 5.1
вмі	$23.3 \pm 4.0$	$26.7 \pm 6.0$	27.1 ± 6.9	29.1 ± 8.2	25.8 ± 5.8	27.2 ± 6.3
Percent Federal Poverty	590.9 ± 315.8	293.3 ± 263.2	337.4 ± 295.1	208.0 ± 245.0	488.3 ± 299.8	394.3 ± 287.1
Gestational Age at Delivery (weeks)	38.9 ± 1.9	38.8 ± 2.0	38.6 ± 2.1	38.4 ± 2.5	38.9 ± 2.0	38.4 ± 2.6

Table 2: Multilevel Poisson regression with outcome blood transfusion. Bolding indicates statistical significance at 95% confidence.

#### 520 RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

521

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
			RR (95% CI)	
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	1.29(1.06 - 1.57)	1.20 ( 0.97 - 1.50 )	1.19 ( 0.95 - 1.50 )	1.21 ( 0.96 - 1.52 )
Hispanic	1.28(1.07 - 1.54)	1.17 ( 0.95 - 1.45 )	1.19(0.96-1.48)	1.19(0.96 - 1.48)
Multiracial	0.98 ( 0.59 - 1.62 )	0.94 ( 0.57 - 1.52 )	0.86 ( 0.54 - 1.36 )	0.84 ( 0.53 - 1.32 )
Asian	0.86 ( 0.47 - 1.59 )	0.85 ( 0.46 - 1.57 )	0.88 ( 0.48 - 1.63 )	0.88 ( 0.48 - 1.63 )
Other	1.25 ( 0.67 - 2.32 )	1.21 ( 0.66 - 2.22 )	1.17(0.66 - 2.06)	1.18(0.67 - 2.09)
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			1.11(0.88 - 1.39)	1.17(0.92 - 1.48)
Endocrine			1.25(1.00 - 1.56)	1.28(1.02 - 1.60)
Kidney			1.28 ( 0.93 - 1.75 )	1.27(0.93 - 1.75)
Hematologic			1.42(1.23 - 1.64)	1.42(1.23 - 1.64)
Autoimmune			1.36(1.04 - 1.78)	1.36(1.04 - 1.79)
Gynecological			0.69 ( 0.48 - 1.00 )	0.73 ( 0.50 - 1.06 )
Combined effects				
Cardiovascular: Endocrine				0.83 ( 0.38 - 1.83 )
Cardiovascular: Gynecological				0.67 ( 0.22 - 2.02 )
Overall AUC	0.56	0.55	0.59	0.59

523 Table 3: Multilevel Poisson regression with outcome postpartum readmission. Bolding indicates statistical significance at 95% confidence.

524	RR, risk ratio; CI	, confidence interval;	AUC, area under the	e receiver operating characteristic curve

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects	
			RR (95% CI)		
Race					
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00	
Non-Hispanic Black	1.17 ( 0.95 - 1.45 )	0.96 ( 0.75 - 1.21 )	0.97 ( 0.76 - 1.24 )	1.01 ( 0.79 - 1.29 )	
Hispanic	1.18 ( 0.98 - 1.43 )	1.05 ( 0.85 - 1.28 )	1.08 ( 0.89 - 1.31 )	1.07 ( 0.88 - 1.30 )	
Multiracial	1.20 ( 0.87 - 1.66 )	1.10 ( 0.79 - 1.53 )	1.04 ( 0.73 - 1.48 )	1.01 ( 0.70 - 1.46 )	
Asian	0.30 ( 0.05 - 1.61 )	0.32 ( 0.06 - 1.71 )	0.29 ( 0.07 - 1.16 )	0.29 ( 0.08 - 1.05 )	
Other	1.42 ( 0.96 - 2.11 )	1.36 ( 0.90 - 2.04 )	1.42(0.94 - 2.16)	1.43 ( 0.95 - 2.15 )	
Confounders					
Pre-Pregnancy Conditions					
Cardiovascular			1.20(1.00 - 1.45)	1.33(1.04 - 1.68)	
Lung			1.10 ( 0.90 - 1.34 )	1.26 ( 0.99 - 1.61 )	
Endocrine			1.19 ( 0.97 - 1.45 )	1.33 ( 1.03 - 1.71 )	
Hematologic			1.14 ( 0.94 - 1.39 )	1.32(1.02 - 1.71)	
Autoimmune			1.55(1.22 - 1.97)	1.52(1.19 - 1.94)	
Neurological			1.09 ( 0.90 - 1.32 )	1.25 ( 0.99 - 1.58 )	
Mental			0.97 ( 0.80 - 1.19 )	1.06 ( 0.85 - 1.31 )	
Combined effects					
Cardiovascular: Neurological				0.84 ( 0.57 - 1.25 )	
Cardiovascular: Endocrine				0.76 ( 0.52 - 1.11 )	
Cardiovascular: Hematologic				0.89 ( 0.61 - 1.32 )	
Lung: Neurological				0.73 ( 0.43 - 1.23 )	
Lung: Endocrine				0.80 ( 0.48 - 1.33 )	
Lung: Hematologic				0.84 ( 0.51 - 1.40 )	
Neurological: Mental				0.79 ( 0.50 - 1.27 )	
Endocrine: Hematologic				0.82 ( 0.47 - 1.43 )	
Hematologic: Gynecological				0.38 ( 0.13 - 1.18 )	
Overall AUC	0.54	0.58	0.58	0.57	

525 Table 4: Multilevel Poisson regression with outcome severe preeclampsia, bolding indicates statistical significance at 95% confidence

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
			RR (95% CI)	
(Intercept)	0.45 ( 0.41 - 0.49 )	0.23 ( 0.16 - 0.33 )	0.23 ( 0.16 - 0.34 )	0.23 ( 0.16 - 0.34 )
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	1.45(1.29 - 1.63)	1.22(1.06 - 1.41)	1.15 ( 0.99 - 1.34 )	1.16 ( 0.99 - 1.35 )
Hispanic	1.09 ( 0.92 - 1.28 )	1.04 ( 0.87 - 1.23 )	0.97 ( 0.82 - 1.14 )	0.97 ( 0.82 - 1.15 )
Multiracial	1.28(1.02 - 1.60)	1.09 ( 0.88 - 1.35 )	1.06 ( 0.85 - 1.32 )	1.06(0.85 - 1.31)
Asian	0.93 ( 0.62 - 1.37 )	0.98 ( 0.67 - 1.43 )	0.96 ( 0.67 - 1.38 )	0.97 ( 0.67 - 1.38 )
Other	1.26(0.81 - 1.96)	1.20 ( 0.78 - 1.86 )	1.21(0.76 - 1.91)	1.21(0.77 - 1.91)
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			1.77(1.61 - 1.96)	1.71(1.54 - 1.89)
Kidney			1.27(1.03 - 1.56)	1.25(1.01 - 1.53)
Hematologic			0.90 ( 0.77 - 1.04 )	0.80 ( 0.59 - 1.08 )
Gastrointestinal			0.71 ( 0.48 - 1.05 )	0.70 ( 0.47 - 1.05 )
Gynecological			0.84 ( 0.70 - 1.02 )	0.85 ( 0.71 - 1.02 )
Combined effects				
Cardiovascular: Hematologic				1.26 ( 0.91 - 1.75 )
Overall AUC	0.56	0.61	0.65	0.65

